6. Cue Biopharma Inc. (NASDAQ:CUE)
An Evolving Immunology Pipeline Adds Fresh Clinical Catalysts
Cue Biopharma, Inc. (NASDAQ: CUE) has an investment story that now extends beyond its earlier association with the Immuno-STAT platform. Its 2026 updates emphasize allergic and autoimmune diseases, including CUE-221 for chronic spontaneous urticaria, commonly known as chronic hives.
In September, the business announced positive topline Phase 2 results from a 145-participant study conducted in China by a related company of its licensing partner. Management reported that the trial met its primary and key secondary endpoints and outlined plans for a Phase 2b/3 study. The findings create a development catalyst, although fuller data and subsequent trials remain necessary to establish the treatment’s potential.
The financial statements also require context. Second-quarter revenue reached $7.9 million, up from approximately $3 million a year earlier, with the increase tied to collaboration milestone revenue. That differs from recurring prescription sales. A subsequent $50 million private placement supplied additional development funding while introducing dilution considerations.
Ranking Rationale
The No. 6 placement reflects a refreshed immunology portfolio, recent clinical progress, and additional capital. Execution risk remains meaningful as the business advances its licensed program and translates preliminary results into a broader regulatory development strategy.
YOU MUST READ THIS: Top 6 Small-Cap Healthcare Stocks to Buy Right Now
Click here to continue reading and checkout the 5 Promising Small-Cap Biotech Stocks to Watch.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
